The efficacy outcomes were the incidence of major adverse cardiovascular events (MACE). MACE was defined as a composite of cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal ischemic stroke. All-cause death, non-fatal stroke, readmission due to angina pectoris, urgent revascularization, and stent thrombosis (defined as definite or probable according to the Academic Research Consortium) were also assessed.